Drug intelligence / Profile preview

STC042

Development stage: Preclinical
Lead developer: Staidson Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

STC042 is a preclinical-stage monoclonal antibody developed by Staidson Biopharmaceutical that targets thymic stromal lymphopoietin (TSLP). TSLP is an epithelial-derived cytokine that acts as an upstream master regulator of type 2 (T2) inflammation, playing a critical role in the pathogenesis of asthma. By binding to and neutralizing TSLP, STC042 is designed to prevent the activation of downstream inflammatory cells and cytokines, potentially offering a treatment option for a broad population of asthma patients, including those with non-eosinophilic profiles.

Targets

TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on STC042.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STC042.

Explore the full profile